# HEM-001: Sickle Cell Crisis (P-selectin) Novel P-selectin inhibitor preventing vaso-occlusive pain crises in sickle cell disease ## Program Overview - **Therapeutic Area:** Hematology - **Indication:** Sickle Cell Vaso-occlusive Crisis - **Target:** P-selectin - **Modality:** Small Molecule - **Stage:** Discovery / Lead Optimization ## Scientific Rationale ### Vaso-Occlusive Crises: A Devastating Complication Sickle cell disease (SCD) affects approximately 100,000 Americans and 20 million people globally, caused by a single point mutation in the β-globin gene. While the molecular defect is well understood, managing vaso-occlusive crises (VOCs)—acute episodes of microvascular obstruction causing excruciating pain, organ damage, and early mortality—remains a critical unmet need. VOCs account for 90% of SCD-related hospitalizations, costing the US healthcare system $1.5B annually, with individual crises lasting 7-10 days. The pathophysiology is complex: deoxygenated sickle hemoglobin polymerizes, deforming erythrocytes into rigid, crescent shapes. These cells adhere abnormally to vascular endothelium through P-selectin-mediated interactions, triggering inflammatory cascades, platelet activation, and microvascular obstruction. Current therapies (hydroxyurea, L-glutamine, voxelotor) reduce crisis frequency by only 25-45%, and crizanlizumab, the only approved anti-P-selectin antibody, requires monthly IV infusions with limited real-world efficacy. ### AI-Designed Oral P-selectin Inhibitor Our AI platform designed a novel small molecule P-selectin inhibitor optimized for chronic oral prophylaxis. Using structure-based drug design, we identified compounds that selectively block the P-selectin binding site critical for sickle erythrocyte adhesion while preserving normal hemostatic function. The lead candidate demonstrates high predicted oral bioavailability with rapid absorption kinetics, enabling once-daily dosing that maintains therapeutic P-selectin blockade throughout circadian peaks in endothelial activation. Computational modeling predicts significantly greater potency than current therapies while maintaining selectivity over related adhesion molecules. ### Digital Patient Modeling We built digital patient models of SCD pathophysiology incorporating diverse genotypes (HbSS, HbSC, HbS/β-thalassemia), fetal hemoglobin levels, and inflammatory states. Simulating our lead candidate across hundreds of these models predicts: - Substantial predicted reduction in VOC frequency with once-daily oral dosing, with efficacy maintained across SCD genotypes including HbSC patients who typically respond poorly to hydroxyurea. An oral small molecule with these properties would address a significant unmet need—providing convenient, daily prophylaxis without the burden of monthly IV infusions required by current anti-adhesion therapies. ## Recent Research Supporting This Approach ### P-selectin's central role in vaso-occlusive pathophysiology Advanced imaging studies and single-cell analyses have revealed that P-selectin-mediated adhesion of sickle erythrocytes to endothelium is the initiating event in vaso-occlusive crises. Blocking this interaction represents a direct mechanism to prevent crisis onset (Blood, 2024; Nature Medicine, 2023). ### Limitations of current anti-adhesion therapies While crizanlizumab demonstrated proof-of-concept for P-selectin inhibition, its modest real-world efficacy and monthly IV dosing highlight the need for more potent, convenient alternatives. Recent studies emphasize the importance of sustained, high-level P-selectin blockade (JAMA, 2023; The Lancet Haematology, 2024). ### Oral small molecule anti-adhesion therapies Recent breakthroughs in structure-based drug design have enabled development of oral small molecule inhibitors targeting adhesion molecules with improved potency and pharmacokinetics. AI-guided optimization accelerates identification of selective candidates with favorable drug-like properties (Nature Biotechnology, 2024; Journal of Medicinal Chemistry, 2023). ## Interested in Licensing HEM-001? Contact us to discuss licensing opportunities and partnership terms.